ArticleFrontiers in pharmacology2025
Multicenter retrospective comparison of safety and efficacy among three antithrombotic regimens following TAVI.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study comprehensively evaluates the safety and efficacy of three antithrombotic regimens following Transcatheter Aortic Valve Implantation (TAVI), focusing on thrombotic and bleeding complications to provide data-driven insights for optimizing postoperative management. Methods: A retrospective cohort analysis included 58 TAVI patients from two medical centers (from August 2022 to July 2024). Patients were assigned to three regimens post-TAVI: Group A (warfarin for 3-6 months transitioned to lifelong aspirin), Group B (warfarin transitioned to rivaroxaban), and Group C (dual antiplatelet therapy transitioned to aspirin). Key exclusion criteria were concurrent cardiac surgeries and severe hepatic or renal dysfunction. Primary outcomes included transfusion rates, bleeding incidents, and thrombotic events. Secondary outcomes included coagulation parameters [international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer] and postoperative hospital stay duration. Results: Transfusion requirements did not differ significantly across groups (p = 0.576). However, significant differences were noted in bleeding events (p = 0.034) and hospital stay duration (p < 0.001) among groups. Group B (warfarin transitioned to rivaroxaban) had the lowest bleeding incidence (0%) and the shortest hospital stay (8.71 ± 3.58 days), compared to Group A (37.5%, 14.71 ± 7.61 days) and Group C (30.0%, 7.50 ± 2.84 days). Transfusion requirements and thrombotic event rates were comparable across groups. APTT was significantly prolonged in Group C (p < 0.001), without corresponding clinical bleeding. Conclusion: Each antithrombotic regimen presented unique clinical benefits and limitations. Transitioning from warfarin to rivaroxaban was associated with a significantly reduced risk of bleeding and shorter hospital stays. Transitioning from dual antiplatelet therapy to aspirin monotherapy significant prolonged APTT without increasing clinical bleeding events. These findings highlight the importance of tailored antithrombotic strategies to optimize post-TAVI outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.